Login to Your Account



Bavarian Nordic, J&J ink $879M deal for MVA-based vaccines

By Cormac Sheridan
Staff Writer

Thursday, July 27, 2017

DUBLIN – Bavarian Nordic A/S has landed another vaccine development deal with Johnson & Johnson, an alliance worth up to $879 million covering the use of its modified vaccinia ankara technology in the development of vaccines against HIV-1 and hepatitis B virus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription